Jun 07, 2023 / 06:30PM GMT
Akash Tewari - Jefferies - Analyst
Good afternoon. I actually had to check the time. We are now in the afternoon. I hope everyone's enjoying day one of our healthcare conference. My name is Akash Tewari. I'm a pharma and biotech analyst here. I have the pleasure of hosting the Madrigal management team today.
I will -- before we get into Q&A on my end, I will hand it off to Paul and team to give some brief introductions and then we'll take it from there.
Paul Friedman - Madrigal Pharmaceuticals, Inc. - CEO
Thank you, Akash. We are Madrigal Pharmaceuticals. We have completed several Phase 3 studies with successful outcomes in nonalcoholic steatohepatitis and we are working diligently to file our NDA under Subpart H looking for accelerated approval. And we've guided to the end of this month to have filed the NDA. That's where we are, and we are anxious to get our document in.
Questions and Answers:
Akash Tewari - Jefferies - AnalystUnderstood. So maybe let's start off with some of the remaining card
Trustpilot
